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The GENCODE exome: sequencing the complete
human exome
Alison J Coffey1,9, Felix Kokocinski1,9, Maria S Calafato1, Carol E Scott1, Priit Palta1,2,3, Eleanor Drury1,
Christopher J Joyce1, Emily M LeProust4,J e nH a r r o w 1, Sarah Hunt1, Anna-Elina Lehesjoki5, Daniel J Turner1,
Tim J Hubbard1 and Aarno Palotie*,1,6,7,8
Sequencing the coding regions, the exome, of the human genome is one of the major current strategies to identify low frequency
and rare variants associated with human disease traits. So far, the most widely used commercial exome capture reagents have
mainly targeted the consensus coding sequence (CCDS) database. We report the design of an extended set of targets for
capturing the complete human exome, based on annotation from the GENCODE consortium. The extended set covers an
additional 5594 genes and 10.3Mb compared with the current CCDS-based sets. The additional regions include potential
disease genes previously inaccessible to exome resequencing studies, such as 43 genes linked to ion channel activity and
70 genes linked to protein kinase activity. In total, the new GENCODE exome set developed here covers 47.9Mb and performed
well in sequence capture experiments. In the sample set used in this study, we identiﬁed over 5000 SNP variants more in the
GENCODE exome target (24%) than in the CCDS-based exome sequencing.
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INTRODUCTION
Exome resequencing is increasingly becoming a standard tool for the
discovery of genes underlying rare monogenic disease and the
discovery of coding variants associated with common disease.1–3
Although the cost of whole-genome sequencing has fallen dramatically
over the last 2–3 years, it is still too expensive to be a useful approach
for the identiﬁcation of variants associated with different phenotypes
in large cohorts. However, the combination of ‘second-generation’
sequencing technologies (reviewed in refs 4,5) with robust and
efﬁcient methods of sequence capture6–9 has enabled the widespread
targeting of the exome.
Exome resequencing studies are, however, currently being
performed using designs based on an incomplete exome, and conse-
quently many medically relevant genes are not being screened in
ongoing large-scale disease studies. The two most widely used com-
mercial kits for capturing the exome target exons from genes in the
consensus coding sequence (CCDS10) consortium database, in addi-
tion to a selection of miRNAs and non-coding RNAs, are NimbleGen
Sequence Capture 2.1M Human Exome Array, http://www.nimblegen.
com/products/seqcap/ and Agilent SureSelect Human All Exon Kit,
http://www.genomics.agilent.com. Although the collaborative effort
behind the CCDS database has provided a high-quality set of
consistently annotated protein-coding regions, there are still many
annotated genes, with solid evidence of transcription, that are not yet
part of this set. In addition, only 21% of CCDS genes have an
alternative spliced variant annotated. To address this shortcoming,
we have designed and experimentally tested a more complete set of
target regions for the human exome, based on the GENCODE
annotation11 (release 2). The GENCODE collaboration is part of the
Encode project and responsible for the annotation and experimental
validation of gene loci on the human genome.
MATERIALS AND METHODS
Bioinformatic bait design
To generate the coordinates for the GENCODE exome, we extracted the
coordinates for a total of 288654 unique exons from 46275 transcripts of
20921 Ensembl12 protein-coding genes (release 53) and 33621 transcripts of
13772 manually annotated protein-coding genes (HAVANA,13 database version
February 2009), together with an additional 1635 miRNA genes (Ensembl/
miRBase). If the coordinates of any of these exons overlapped by one or more
base pairs, regardless of strand, the overlapping exons were clustered together
into expressed cluster regions (ECRs). A 10bp ﬂank was added on both sides of
each ECR. Any ECR that now overlapped as a result of this ﬂank by at least 1bp
was merged. This resulted in 207108 ECRs, covering B39.3Mb as the design
target (35.2Mb of exonic sequence plus 4.1Mb of ﬂanking sequence). The
coordinates of these regions were used for bait design. The baits were created
using the Agilent SureSelect design algorithm in three rounds of design using
RepeatMasker- and WindowMasker-deﬁned repeats in an attempt to avoid
repetitive regions as well as to increase coverage of the target exons. Each
successive round of design was more permissive of repeat overlap (0, 20 and
40bp). After sequencing, the underperforming baits were boosted at speciﬁc
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of baits relative to repeat regions, the boosting was done either by direct
replication or by shifting the booster bait either up or downstream by 30bp. It
was possible to design baits to 205031 of the ECRs or 99% of the GENCODE
exome target regions (Table 1). The total size of these ﬁnal bait regions is
47.9Mb.
Sequence capture and sequencing
In all, 15mg of DNA diluted in TE was sheared to 100–400bp using a Covaris
S2 (Covaris, Woburn, MA, USA). Sheared samples were quantiﬁed on a
Bioanalyzer 2100 (Agilent, Santa Clara, CA, USA), and 7.5mlo fC O T1D N A
at 100ng/ml was added. This library was lyophilised in a vacuum concentrator
to a pellet and resuspended in 3.4ml of ultrapure water. Following Agilent’s
SureSelect protocol,14 10mg of sheared DNA were end repaired and polyA
tailed, and Illumina-sequencing adapters were ligated to the resulting fragments
using the Illumina (San Diego, CA, USA) Paired-End DNA Sample-Prep
protocol, except that the gel-size selection step was replaced with a puriﬁcation
using magnetic bead-based solid phase reversible immobilisation (SPRI) beads
(following Agilent’s protocol14). The capture library was prepared by mixing
5ml of the oligo capture library, 1.5ml of ultrapure water and 1mlo f1 : 1d i l u t i o n
of RNase block. In all, 500ng of each sample library was hybridised to the
appropriate bait set in PCR plates on a thermocycler at 651C for 24h
(following the manufacturer’s protocol with the modiﬁcation that no prehy-
bridisation PCR was performed). The capture was performed according to the
manufacturer’s protocol with streptavidin-coated Dynal beads (Invitrogen,
Paisley, UK), and captured samples were washed three times using SureSelect
wash buffers with a series of incubation steps. The samples were cleaned up
using Mini Elute columns (Qiagen, Hilden, Germany) and eluted in 50mlo f
PCR-grade water. Eluted samples were ampliﬁed using a master-mix containing
2m M MgCl2, 0.2mM dNTPs, 0.5mM PE.1, 0.5mM PE.2 and 3 units of Platinum
Pfx DNA Polymerase (Invitrogen) per sample. Samples were aliquoted into
three individual wells of a plate and ampliﬁed using the following conditions:
941C for 5min, followed by 20 cycles of 941C for 15s, 581C for 30s, 721C
for 30s and a ﬁnal extension of 721C for 5min. PCR products were puriﬁed
using SPRI beads before sequencing. All data represent results of one capture
reaction for each sample. Captured libraries were sequenced on the Illumina
Genome Analyzer 2 platform as paired-end 54-bp reads according to the
manufacturer’s protocol. The presequencing preparation time is about 3 days,
where sonication and library creation take B1d a y ,a n dh y b r i d i s a t i o na n d
ampliﬁcation 1 day each.
Bioinformatics analysis
Reads were aligned to the human genome (NCBI36) using the MAQ software
package v0.7.1.15 Base qualities were recalibrated using the Genome Analysis
Toolkit v1.0.3540 (http://www.broadinstitute.org/gsa/wiki/index.php/The_
Genome_Analysis_Toolkit) and duplicate fragments marked using Picard
v1.17 (http://picard.sourceforge.net/). SNPs were called using SAMtools
v0.1.716 and GATK, and the intersection of the resulting call sets in the target
regions (39.3Mb) with a sequence read depth of Z8  were reported. Coverage
comparisons of the different target set locations were done using BEDTools
v.2.6.0.17
RESULTS
A comparison of the coverage of the bait/oligonucleotide positions of
the available CCDS-based exome sets and the GENCODE exome with
the set of GENCODE design targets (Table 1) illustrates the increased
coverage of our extended target set. The bait positions of the
GENCODE exome cover 99% of the targets, which represents an
additional 59600 exons available for capture that are not present in
either one of the CCDS-based sets (Supplementary Data 3). The
missing 1% consists of regions where reliable bait design was not
possible. Comparison of exon and transcript coverage between
bait/oligonucleotide locations of the available exome sets and the
GENCODE exome, and three current reference gene sets (Figure 1),
shows that in all cases, the GENCODE exome covers a greater
percentage of the reference gene sets. For example, there is an
additional 9% of the exons from the CCDS database and 12% of
the exons from RefSeq covered by our expanded target set.
The content present in the GENCODE exome exclusively consists of
38933 cluster regions, which contain 5594 additional genes of the
design target. The 4363 distinct Ensembl-53-based genes of this set
contain 1881 (43%) genes that have an ofﬁcial HGNC identiﬁer, 711
(16%) that are linked to an OMIM entry and 1410 (32%) that have
Gene Ontology annotation (Supplementary Data 4). In all, 41%
(1809) of these genes have no external annotation of this kind and
as such represent novel genes, which could prove to be an important
source of variation. The content of repetitive/low-complexity sequence
in the bait sets is comparable. The ratios of bases masked by
RepeatMasker, Dust and TRF against the total bases in the sets are
Nimblegen CCDS: 0.027, Agilent CCDS: 0.021 and GENCODE
exome: 0.027 (Supplementary Table 3). A comparison with a sequence
uniqueness mask is given in Supplementary Table 4 and supports these
ﬁndings. The list of 5594 genes and regions targeted by the
GENCODE exome exclusively is available as supplementary data
and on our ftp site (http://ftp.sanger.ac.uk/gencode/exome), as well
as data for the full GENCODE exome and the initial design target. The
406539 bait locations are supplied as a Distributed Annotation System
data source as well (das.sanger.ac.uk/das/Exome), which can be dis-
played in genome browsers like Ensembl (version 53; http://tinyurl.
com/browse-exome).
To evaluate the performance of the GENCODE exome, DNA from
three HapMap individuals (NA12878, NA07000 and NA19240) was
subjected to sequence capture using both the Agilent SureSelect
Human All Exon kit and baits designed to the GENCODE exome.
Table 1 Comparison of the coverage of the design target between the
three exome sets
Nimblegen CCDSa Agilent CCDSb GENCODE exome
No. of bait regions 197218 316000 406539
Genome coverage (Mb) 34.1 37.6 47.9c (35.2)d
ECRs covered (%) 150529 (72.7) 164225 (79.3) 205031 (99.0)
Transcripts covered (%) 66828 (81.0) 71279 (86.4) 81204 (98.4)
Genes covered (%) 28203 (76.5) 30030 (81.5) 35989 (97.7)
aNimbleGen Sequence Capture 2.1M Human Exome Array.
bAgilent SureSelect Human All Exon Kit.
cTotal length of bait regions including ﬂanking regions.
dTheoretical length without ﬂanking regions.
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Figure 1 Comparison of exon and transcript coverage between
oligonucleotide locations of the available exome kits and current reference
gene sets (CCDS database March 2010, RefSeq genes March 2010 and
GENCODE version 3c). The histogram shows the near-complete coverage by
the GENCODE exome of all reference sets. Full data are given in
Supplementary Table 1.
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samples, DNA from seven individuals recruited from a clinical
neurological unit was subjected to sequence capture using baits
designed to the GENCODE exome. All samples were sequenced as
described in the methods section. On average, 97% of reads could be
successfully mapped back for both the GENCODE and the Agilent
CCDS set. Full details of the sequence yield and reads mapping back to
target are given in Supplementary Table 2 (coverage was reported only
using reads with a mapping quality of Z10). The average fold
coverage for the HapMap exomes for the CCDS-based targets was
73-fold from 9.2Gb of sequence and for the GENCODE exome,
82-fold from 11.5Gb of sequence. The average fold coverage for the
clinical samples was 58-fold from 7.5Gb of sequence. On average for
the HapMap samples, 96% of targeted bases were covered at least once
and 90% were covered at greater than or equal to eightfold for the
CCDS exome, with similar ﬁgures for the GENCODE exome of
92 and 83% (Figure 2a). The clinical samples gave an average for
the GENCODE exome of 95% of targeted bases covered at least once
and 88% covered at greater than or equal to eightfold (Supplementary
Figure 1). The results demonstrate that on average, the GENCODE-
only regions perform equally to the CCDS regions.
An average of 22271 SNPs, of which 2.6% were novel, were found
for the HapMap GENCODE exomes compared with 18554, of which
1.7% were novel, for the CCDS-based exome (Table 2; it should be
noted that for most samples, only one lane of the sequencing machine
was used. Thus, the sequencing depth does not allow to identify all
possible variants, slightly underestimating the number of identiﬁed
variants). In this instance, novel is deﬁned as not being present in
dbSNP18 (version 130) or 1000 Genomes project (1000 Genomes
Project Consortium, http://www.1000genomes.org, released on 26
March 2010). An average of 21866 variants, of which 4.2% were
novel, was found in the clinical samples. The clinical samples had been
previously genotyped on the Illumina 660K chip that allowed the
concordance rate of the variants found in common with exome
sequencing using the GENCODE exome to be calculated at 99.8%.
Of the 62 sites, which were discrepant between array genotyping and
sequencing, 47 were discrepant only in one sample, suggesting that the
number of systematic genotyping errors is low. The ratio of STOP
codons gained is approximately in proportion to the size of the exome
being captured, suggesting that the extra material in the GENCODE
exome does not represent or select for a signiﬁcant excess of pseudo-
genes (1.2:1 for the CCDS-based exome in comparison with 1.8:1 for
the GENCODE exome). The 22002 SNPs found on average in the
GENCODE exome-captured samples included a mean per sample of
9006 non-synonymous variants, 9424 synonymous variants and 91
stop-gained variants. Therefore, on average, 268 synonymous variants,
256 non-synonymous variants and 2.6 stop-gained variants were
found per megabase of the 35.2-Mb targeted genomic sequence,
corresponding to a total of 626.6 variants/Mb. In the CCDS-based
exome-captured sample among the 18554 coding SNPs found on
average, there was a mean per sample of 7585 non-synonymous
variants, 8880 synonymous variants and 45 stop-gained variants,
corresponding to 512 variants/Mb.
DISCUSSION
The GENCODE gene set as the basis for our exome design provides a
more complete set of targets, as it is a merger of the slower but
thorough manual Havana and the genome-wide automatic Ensembl
annotation. Both Havana and Ensembl are part of the CCDS con-
sortium, and all of the agreed CCDS structures at the time of
construction have been incorporated into the new target set.
The new design includes relevant genes for disease-associated
variant and mutation discovery. Among the genes in the new,
expanded set are members of well-characterised gene families, which
are associated with important medical conditions. For example, 43
genes are linked to ion channel activity. Mutations in ion channel
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Figure 2 Coverage achieved by the GENCODE exome. (a) Cumulative fold
coverage plot for HapMap samples captured with Agilent SureSelect Human
All Exon Kit (CCDS), the GENCODE exome, and the regions covered by the
GENCODE exome only. Similar data are presented for the clinical samples
and the GENCODE exome only in Supplementary Figure 1. In all cases, the
thin red vertical line indicates a fold coverage of eightfold, the preferred
coverage required for variant calling. (b and c) Detailed view of the average
sequence depth of the seven clinical samples across the entire gene region
post sequence capture of two example genes that are unique to the
GENCODE exome: (b) ABCB11 and (c) XPC. In the upper part of each
panel, the positions of the baits from the GENCODE exome are given as dark
grey boxes above the exon structure (adapted from the Ensembl genome
browser) of each gene in red. The increased sequencing depth of the eights
exon of XPC is caused by good coverage of this larger exon with eight
different bait sequences, whereas the other smaller exons are covered by
one or two baits.
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European Journal of Human Geneticsgenes are known to cause a range of channelopathies, including
arrhythmias and inherited paroxysmal neurological disorders.19 Also,
the recently identiﬁed MLL2 gene linked to the Kabuki syndrome20
was not covered in the CCDS exome but is now represented in the
expanded GENCODE exome. There are 70 genes linked to kinase
activity. Deregulated protein kinase activity is frequently associated
with, and members of the protein kinase family are commonly
mutated in, cancer and are thus desired to be covered in cancer
sequencing studies. Furthermore, protein kinases are considered to be
the targets for the development of new anticancer therapies.21
The sequence capture of the clinical samples for two genes that are
targeted by the GENCODE exome only, ABCB11 and XPC, (Figures
2b and c) demonstrates that we have been able to design baits for
genes that are unique to the GENCODE exome, and capture them
efﬁciently, with a high degree of speciﬁcity. Each exon is covered by a
read depth of substantially more than eightfold, which is preferred for
variant calling. ABCB11 and XPC genes are already associated with
disease, and provide examples of candidate disease genes that are
missing from the existing exome-sequencing kits. Indeed, use of the
GENCODE exome has already allowed the identiﬁcation of a patho-
genic mutation in a gene causing an autosomal recessive Dwarﬁsm
syndrome, which would not have been discovered using a standard
CCDS-based exome.22
The advent of the GENCODE exome represents a substantial
improvement to the currently available designs for exome sequencing,
allowing the capture of a more complete target. We estimate that we
were able to call variants in 84% of the total GENCODE exome. This
fraction of callable exome regions is likely to increase further with
improving sequencing technology and sequencing depths. The
GENCODE exome design is being used by the International Cancer
Genome Consortium (ICGC; http://www.icgc.org) for their exome-
sequencing programme as part of their aim to obtain a comprehensive
description of different tumour types and by the UK10K project
(http://www.uk10k.org).
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no. 7 NA12878 NA07000 NA19240 NA12878 NA07000 NA19240
Bait library GENCODE exome Agilent CCDS
SNPs (polymorphic
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